{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T09:10:07Z","timestamp":1756804207427,"version":"3.44.0"},"reference-count":75,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15202","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:39:11Z","timestamp":1753184351000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Acute myeloid leukemia with plasmacytoid dendritic cell proliferation: A case report and literature review"],"prefix":"10.3892","volume":"30","author":[{"given":"Zhixin","family":"Pei","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Experimental and Translational Non\u2011coding RNA Research, Yangzhou University Medical College, Yangzhou, Jiangsu 225009, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Pei","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingxin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People's Hospital, Jiaozuo, Henan 454000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"key20250902113521_b1-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.3390\/ijms19123850","article-title":"Genetic hierarchy of acute myeloid leukemia: From clonal hematopoiesis to molecular residual disease","volume":"19","author":"Martignoles","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20250902113521_b2-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.stem.2015.08.011","article-title":"Hematopoietic differentiation is required for initiation of acute myeloid leukemia","volume":"17","author":"Ye","year":"2015","journal-title":"Cell Stem Cell"},{"key":"key20250902113521_b3-ol-30-4-15202","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20250902113521_b4-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"\u2018Acute myeloid leukemia: A comprehensive review and 2016 update\u2019","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"author":"National Cancer Institute","article-title":"Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Leukemia-Acute Myeloid Leukemia (AML)","key":"key20250902113521_b5-ol-30-4-15202"},{"key":"key20250902113521_b6-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: Conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"key20250902113521_b7-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1200\/JCO-24-01841","article-title":"Hematopoietic stem cell transplantation outcomes for high-risk AML: A report from the children's oncology group","volume":"43","author":"Huang","year":"2025","journal-title":"J Clin Oncol"},{"key":"key20250902113521_b8-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41419-019-2156-2","article-title":"Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML","volume":"10","author":"Ewald","year":"2019","journal-title":"Cell Death Dis"},{"issue":"(1S)","key":"key20250902113521_b9-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/j.bulcan.2024.02.006","article-title":"Preventive and therapeutic strategies for relapse after hematopoietic stem cell transplant for pediatric AML (SFGM-TC)","volume":"112","author":"Renard","year":"2025","journal-title":"Bull Cancer"},{"key":"key20250902113521_b10-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00277-013-1940-9","article-title":"Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)","volume":"93","author":"Tawfik","year":"2014","journal-title":"Ann Hematol"},{"key":"key20250902113521_b11-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11899-016-0339-9","article-title":"What is the optimal induction therapy for younger fit patients with AML?","volume":"11","author":"Fernandez","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"key20250902113521_b12-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"key":"key20250902113521_b13-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3390\/cells13161392","article-title":"Common driver mutations in AML: Biological impact, clinical considerations, and treatment strategies","volume":"13","author":"Nong","year":"2024","journal-title":"Cells"},{"key":"key20250902113521_b14-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.3390\/cancers16233974","article-title":"Inflammation and Related signaling pathways in acute myeloid leukemia","volume":"16","author":"Naji","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20250902113521_b15-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1158\/1078-0432.CCR-12-2087","article-title":"The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia","volume":"19","author":"Lee","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20250902113521_b16-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.clml.2021.07.007","article-title":"Molecular characterization and clinical treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients with TP53 mutation","volume":"21","author":"Li","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20250902113521_b17-ol-30-4-15202","first-page":"7285","article-title":"Tumor-forming plasmacytoid dendritic cells in acute myelocytic leukemia: A report of three cases and literature review","volume":"10","author":"Wang","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"key20250902113521_b18-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11912-021-01108-9","article-title":"3+7 combined chemotherapy for acute myeloid leukemia: Is it time to say goodbye?","volume":"23","author":"Tang","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"key20250902113521_b19-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jgo.2015.10.182","article-title":"Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)","volume":"7","author":"Tawfik","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"key20250902113521_b20-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-020-00964-1","article-title":"Management of acute myeloid leukemia (AML) in older patients","volume":"22","author":"Abdallah","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"key20250902113521_b21-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3324\/haematol.2014.117267","article-title":"Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia","volume":"100","author":"Medeiros","year":"2015","journal-title":"Haematologica"},{"key":"key20250902113521_b22-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3324\/haematol.2020.260562","article-title":"ZRSR1 Co-operates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells","volume":"107","author":"Madan","year":"2022","journal-title":"Haematologica"},{"key":"key20250902113521_b23-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-20-1513","article-title":"Sex-Biased ZRSR2 mutations in myeloid malignancies impair plasmacytoid dendritic cell activation and apoptosis","volume":"12","author":"Togami","year":"2022","journal-title":"Cancer Discov"},{"key":"key20250902113521_b24-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00277-024-05885-8","article-title":"Significance of targeting DNMT3A mutations in AML","volume":"104","author":"Huang","year":"2025","journal-title":"Ann Hematol"},{"key":"key20250902113521_b25-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11596-025-00042-2","article-title":"Targeting calprotectin S100A8\/A9 to overcome AML progression in DNMT3A-Mutant cells","volume":"45","author":"Cai","year":"2025","journal-title":"Curr Med Sci"},{"key":"key20250902113521_b26-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e163864","DOI":"10.1172\/jci.insight.163864","article-title":"Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway","volume":"8","author":"Palam","year":"2023","journal-title":"JCI Insight"},{"key":"key20250902113521_b27-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1182\/bloodadvances.2018024422","article-title":"RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs","volume":"3","author":"Gerritsen","year":"2019","journal-title":"Blood Adv"},{"key":"key20250902113521_b28-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12185-023-03586-y","article-title":"Epigenetic regulation by ASXL1 in myeloid malignancies","volume":"117","author":"Yang","year":"2023","journal-title":"Int J Hematol"},{"key":"key20250902113521_b29-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-022-01336-x","article-title":"ASXL1\/2 mutations and myeloid malignancies","volume":"15","author":"Medina","year":"2022","journal-title":"J Hematol Oncol"},{"key":"key20250902113521_b30-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1007\/s00277-024-06001-6","article-title":"Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival","volume":"103","author":"Duan","year":"2024","journal-title":"Ann Hematol"},{"key":"key20250902113521_b31-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3233\/CBM-210024","article-title":"Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study","volume":"32","author":"Ebian","year":"2021","journal-title":"Cancer Biomark"},{"key":"key20250902113521_b32-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e18656","DOI":"10.7717\/peerj.18656","article-title":"The epigenetic role of EZH2 in acute myeloid leukemia","volume":"12","author":"Fang","year":"2024","journal-title":"PeerJ"},{"key":"key20250902113521_b33-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13148-021-01087-5","article-title":"Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML\/MDS patients","volume":"13","author":"Stomper","year":"2021","journal-title":"Clin Epigenetics"},{"key":"key20250902113521_b34-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2147\/OTT.S384293","article-title":"Therapeutic targeting of FLT3 in acute myeloid leukemia: Current status and novel approaches","volume":"15","author":"Tecik","year":"2022","journal-title":"Onco Targets Ther"},{"key":"key20250902113521_b35-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/bloodadvances.2020003443","article-title":"SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML","volume":"5","author":"Pacharne","year":"2021","journal-title":"Blood Adv"},{"key":"key20250902113521_b36-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1007\/s00277-024-05917-3","article-title":"Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations","volume":"103","author":"Li","year":"2024","journal-title":"Ann Hematol"},{"key":"key20250902113521_b37-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"280","DOI":"10.6004\/jnccn.2011.0027","article-title":"Acute myeloid leukemia","volume":"9","author":"O'Donnell","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"key20250902113521_b38-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.leukres.2018.01.002","article-title":"Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation","volume":"65","author":"Cui","year":"2018","journal-title":"Leukemia Res"},{"key":"key20250902113521_b39-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"13576","DOI":"10.1073\/pnas.1301891110","article-title":"Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation","volume":"110","author":"Miraki-Moud","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20250902113521_b40-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/jcm8050579","article-title":"Dendritic cell-based immunotherapy of acute myeloid leukemia","volume":"8","author":"Van Acker","year":"2019","journal-title":"J Clin Med"},{"key":"key20250902113521_b41-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20250902113521_b42-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","article-title":"FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"key20250902113521_b43-ol-30-4-15202","first-page":"3829","article-title":"BCL-2 inhibitor synergizes with PI3K\u03b4 inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia","volume":"12","author":"Yao","year":"2022","journal-title":"Am J Cancer Res"},{"key":"key20250902113521_b44-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1021\/acs.biomac.4c00561","article-title":"CXCR4-mediated codelivery of FLT3 and BCL-2 inhibitors for enhanced targeted combination therapy of FLT3-ITD acute myeloid leukemia","volume":"25","author":"Yang","year":"2024","journal-title":"Biomacromolecules"},{"key":"key20250902113521_b45-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1158\/1078-0432.CCR-17-2796","article-title":"IDH1\/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1\/2-mutant inhibitors","volume":"24","author":"Molenaar","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20250902113521_b46-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1945803","DOI":"10.1080\/2162402X.2021.1945803","article-title":"Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment","volume":"10","author":"Bonnevaux","year":"2021","journal-title":"Oncoimmunology"},{"key":"key20250902113521_b47-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"806243","DOI":"10.3389\/fonc.2021.806243","article-title":"Post-hoc analysis of pharmacodynamics and single-agent activity of CD3\u00d7CD123 bispecific antibody APVO436 in relapsed\/refractory AML and MDS resistant to HMA or venetoclax plus HMA","volume":"11","author":"Watts","year":"2022","journal-title":"Front Oncol"},{"key":"key20250902113521_b48-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"key20250902113521_b49-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e35845","DOI":"10.1002\/cncr.35845","article-title":"Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia","volume":"131","author":"Leber","year":"2025","journal-title":"Cancer"},{"key":"key20250902113521_b50-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e0279063","DOI":"10.1371\/journal.pone.0279063","article-title":"Novel dual LSD1\/HDAC6 inhibitor for the treatment of cancer","volume":"18","author":"Gajendran","year":"2023","journal-title":"PLoS One"},{"key":"key20250902113521_b51-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"127763","DOI":"10.1016\/j.bmcl.2020.127763","article-title":"Novel dual LSD1\/HDAC6 inhibitors for the treatment of multiple myeloma","volume":"34","author":"Naveen Sadhu","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"key20250902113521_b52-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/0008-5472.CAN-23-2729","article-title":"Genome-Wide CRISPR screens identify multiple synthetic lethal targets that enhance KRASG12C inhibitor efficacy","volume":"83","author":"Mukhopadhyay","year":"2023","journal-title":"Cancer Res"},{"key":"key20250902113521_b53-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"189212","DOI":"10.1016\/j.bbcan.2024.189212","article-title":"Developing pioneering pharmacological strategies with CRISPR\/Cas9 library screening to overcome cancer drug resistance","volume":"1879","author":"He","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20250902113521_b54-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12026-012-8353-z","article-title":"Using functional genomics to overcome therapeutic resistance in hematological malignancies","volume":"55","author":"Alvarez-Calderon","year":"2023","journal-title":"Immunol Res"},{"key":"key20250902113521_b55-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"878","DOI":"10.18632\/oncotarget.27949","article-title":"Activation of plasmacytoid dendritic cells promotes AML-cell fratricide","volume":"12","author":"Fatehchand","year":"2021","journal-title":"Oncotarget"},{"key":"key20250902113521_b56-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/cancers14030756","article-title":"Molecular systems architecture of interactome in the acute myeloid leukemia microenvironment","volume":"14","author":"Ayyadurai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20250902113521_b57-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.2147\/CMAR.S260825","article-title":"Plasmacytoid dendritic cell infiltration in acute myeloid leukemia","volume":"12","author":"Zhu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"key20250902113521_b58-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"key20250902113521_b59-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.3324\/haematol.2020.253740","article-title":"Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: Phenotype profile and mutation landscape","volume":"106","author":"Zalma\u00ef","year":"2020","journal-title":"Haematologica"},{"key":"key20250902113521_b60-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.3390\/cancers14143375","article-title":"Immunophenotypic and molecular features of acute myeloid leukemia with plasmacytoid dendritic cell differentiation are distinct from blastic plasmacytoid dendritic cell neoplasm","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20250902113521_b61-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.a.23953","article-title":"Myeloid neoplasms with elevated plasmacytoid dendritic cell differentiation reflect the maturation process of dendritic cells","volume":"97","author":"Huang","year":"2020","journal-title":"Cytometry A"},{"key":"key20250902113521_b62-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/BS9.0000000000000097","article-title":"Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells","volume":"4","author":"Gong","year":"2022","journal-title":"Blood Sci"},{"key":"key20250902113521_b63-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1002\/cpz1.50","article-title":"Phenotypic and functional study of human plasmacytoid dendritic cells","volume":"1","author":"Li","year":"2021","journal-title":"Curr Protoc"},{"key":"key20250902113521_b64-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood.2020007897","article-title":"Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia","volume":"137","author":"Xiao","year":"2021","journal-title":"Blood"},{"key":"key20250902113521_b65-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41375-019-0447-3","article-title":"Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia","volume":"33","author":"Lucas","year":"2019","journal-title":"Leukemia"},{"key":"key20250902113521_b66-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1476-4598-13-159","article-title":"Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents","volume":"13","author":"Klanova","year":"2014","journal-title":"Mol Cancer"},{"key":"key20250902113521_b67-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e1477460","DOI":"10.1080\/2162402X.2018.1477460","article-title":"IMiDs mobilize acute myeloid leukemia blasts to peripheral blood through downregulation of CXCR4 but fail to potentiate AraC\/Idarubicin activity in preclinical models of non del5q\/5q-AML","volume":"7","author":"Lopez-Millan","year":"2018","journal-title":"Oncoimmunology"},{"key":"key20250902113521_b68-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e35840","DOI":"10.1002\/cncr.35840","article-title":"Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and\/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial","volume":"131","author":"Goulart","year":"2025","journal-title":"Cancer"},{"key":"key20250902113521_b69-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"eaax2863","DOI":"10.1126\/scitranslmed.aax2863","article-title":"Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response","volume":"11","author":"Sharon","year":"2019","journal-title":"Sci Transl Med"},{"key":"key20250902113521_b70-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/j.clml.2023.12.010","article-title":"Recent advances in the biology and CD123-directed treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"24","author":"Pemmaraju","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20250902113521_b71-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1016\/S2152-2650(22)01287-3","article-title":"Poster: AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies","volume":"22","author":"Pammaraju","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20250902113521_b72-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/17474086.2021.1988848","article-title":"Targeting CD123 in BPDCN: An emerging field","volume":"14","author":"DiPippo","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"key20250902113521_b73-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1080\/21645515.2020.1788299","article-title":"Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia","volume":"16","author":"Aldoss","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"key20250902113521_b74-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S2152-2650(20)30466-3","article-title":"Targeting CD123 in AML","volume":"20","author":"Lane","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20250902113521_b75-ol-30-4-15202","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.3390\/cancers14143545","article-title":"Plasmacytoid dendritic cells, a novel target in myeloid neoplasms","volume":"14","author":"Roussel","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T08:35:28Z","timestamp":1756802128000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":75,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15202","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}